Continue Reading Below
As of 1:18 p.m. EDT on Thursday, shares of Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) are up 13.7%, while shares of its biotech peer Ionis Pharmaceuticals Inc. (NASDAQ: IONS) are down 8.1%.
Investors are cheering positive results from the late-stage Apollo trial with Alnylam's lead candidate, patisiran. The top-line data suggest patisiran could have a competitive edge over a candidate being developed by Ionis.
Alnylam's rally today probably would have been more dramatic if it hadn't already told everyone the Apollo trial met its primary endpoint over a month ago. Today's announcement included more details that don't bode well for Ionis and its related candidate, inotersen.
In partnership with Sanofi (NYSE: SNY), Alnylam is developing patisiran for the treatment of nerve damage caused by a buildup of misfolded transthyretin. After 18 months of treatment, patients given patisiran exhibited a 34-point benefit on the mNIS+7 scale, a generally accepted scale of disease activity, compared to those receiving a placebo.
Continue Reading Below
Patisiran wasn't evaluated in a head-to-head study with Ionis' candidate, but a comparison of available data might explain why Ionis' former partner GlaxoSmithKline handed back all rights to inotersen a few months ago. Even if Ionis eventually launches inotersen, its 19.7-point benefit over placebo, observed on the mNIS+7 scale at 15 months, strongly favors Alnylam's drug.
Patisiran is the most advanced of several programs in Alnylam's clinical-stage development pipeline, and investors can look forward to a flurry of activity in the quarters ahead. The company intends to place an application for patisiran in front of the Food and Drug Administration before the end of the year.
An approval and commercial launch would trigger milestone payments from Sanofi that Alnylam can use to accelerate development of several more candidates in late-stage development, including a program for givosiran, a rare-liver-disease drug that could be ready to submit an FDA application next year.
10 stocks we like better than Alnylam Pharmaceuticals
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Alnylam Pharmaceuticals wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of October 9, 2017